FINWIRES · TerminalLIVE
FINWIRES

Amgen's Q1 EPS Beat Driven Lower Taxes, SG&A, Morgan Stanley Says

By

Amgen's (AMGN) posted in-line Q1 revenue, but EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said in a Friday research report.

The brokerage said it sees favorable access dynamics for the company's Uplinza, which could become the first-line choice for appropriate patients. The company also announced the trials of the MariTide drug for obesity and type 2 diabetes.

Morgan Stanley said it awaits further developments on Tavneos, for which FDA proposed to withdraw the approval, alleging ChemoCentryx manipulated the clinical data. Amgen may seek a hearing on this proposal, analysts said. While the company continues to believe in Tavneos' benefit-risk profile, the firm said the removal of the drug from its model would impact the price target.

The brokerage said it reiterated its equalweight rating on the stock and boosted its price target to $332 per share from $326.

Price: $329.27, Change: $-16.99, Percent Change: -4.91%

Related Articles

Wire

Tanger Q1 Core FFO, Revenue Rise; 2026 Guidance Increased

Tanger (SKT) reported Q1 core funds from operations late Thursday of $0.59 per diluted share, up from $0.53 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended March 31 rose to $150.4 million from $135.4 million a year earlier.Analysts surveyed by FactSet expected $142.9 million.The company raised 2026 FFO guidance to $2.42 to $2.50 per diluted share from $2.41 to $2.49.Analysts polled by FactSet expect $2.47.Tanger shares fell 2.3% in after-hours trading.

$SKT
Wire

Alignment Healthcare Swings to Q1 Profit, Revenue Rises; Shares Fall After Hours

Alignment Healthcare (ALHC) reported Q1 earnings late Thursday of $0.05 per diluted share, compared with the loss of $0.05 a year earlier.Analysts polled by FactSet expected earnings of $0.01.Revenue in the three months ended March 31 rose to $1.24 billion from $926.9 million a year ago.Analysts surveyed by FactSet expected $1.22 billion.The company expects revenue of $1.3 billion to $1.32 billion in Q2 and $5.16 billion to $5.21 billion in the full year.Analysts project $1.31 billion in Q2 and $5.17 billion in 2026.Alignment Healthcare shares fell 10% in after-hours trading.

$ALHC
Wire

GoDaddy Q1 Earnings, Revenue Rise; Shares Gain After Hours

GoDaddy (GDDY) reported Q1 earnings late Thursday of $1.60 per diluted share, up from $1.51 a year earlier.Analysts polled by FactSet expected $1.52.Revenue in the three months ended March 31 rose to $1.27 billion from $1.19 billion a year earlier.Analysts surveyed by FactSet expected $1.26 billion.The company expects Q2 revenue of $1.29 billion to $1.31 billion. Analysts surveyed by FactSet expect $1.29 billion.GoDaddy reaffirmed 2026 revenue guidance of $5.2 billion to $5.28 billion. Analysts surveyed by FactSet expect $5.24 billion.In Q1, the company repurchased 3 million shares for $279.7 million.GoDaddy shares rose 4.2% in after-hours trading.

$GDDY